On August 6, Dentsply Sirona (NASDAQ:XRAY) reported second-quarter 2026 results that pulled the stock in two directions at once. Net sales fell 4.1% year over year to $898 million, yet the company swung from a $45 million net loss a year earlier to $37 million in net income, with diluted earnings per share of $0.18 versus a $0.22 loss. Investors are left weighing a real profitability turnaround against a top line that is still shrinking.
Margins Doing The Heavy Lifting
GAAP gross margin climbed to 54.9% from 52.4% a year ago, and adjusted gross margin came in at 56.4%. Adjusted EBITDA margin ticked up slightly to 21.3% from 21.1%. Cash generation improved even more sharply. Operating cash flow jumped to $99 million from $48 million in the second quarter of 2025, helped by roughly $44 million in tariff refunds along with tighter management of inventory and payables. Free cash flow more than tripled to $55 million from $16 million. The company used some of that cash to repurchase 1.3 million shares for about $12 million during the quarter, and it also expanded its partnership with Medline Sinclair to broaden access to its Connected Technology Solutions portfolio across Canada.
Wellspect Healthcare was the lone segment posting real growth, with net sales up 7.1% to $86 million, and EMEA sales as reported were essentially flat at 0.2% growth. There were no goodwill or intangible asset impairments this quarter, a contrast to the $235 million charge taken in the same period last year. Despite the sales decline, the company reiterated its full-year 2026 outlook of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.
Where The Growth Went Missing
The headline sales decline understates the underlying softness. On a constant currency basis, net sales fell 6.3%, meaning currency translation actually flattered the reported number. Orthodontic and Implant Solutions was the weakest segment, with sales dropping 13.2% to $197 million from $226 million a year ago. The Americas region fared worst geographically, with net sales down 10.7% as reported and 11.6% in constant currency.
Even the adjusted numbers show cracks: adjusted EPS of $0.52 was actually down 1.6% from a year earlier, despite the improved GAAP figures. The balance sheet tightened too, with cash and equivalents falling to $239 million from $326 million at the end of 2025, against long-term debt of nearly $2 billion. Restructuring and other costs for the first six months of 2026 totaled $69 million, up sharply from $13 million in the same period a year ago, tied in part to costs from a new global ERP system.
A Cheap Stock Under Pressure
Hedge fund ownership fell from 41 funds to 36 in the most recent quarter, pointing to institutions trimming their positions rather than adding to them. Short interest sits at 11.01% of float, a double-digit figure that signals a real bear camp has built up around the stock. Yet shares trade at a forward P/E of just 6.97 as of September 2, a multiple that prices in little to no growth ahead. That mix suggests that the market remains unconvinced the turnaround has legs.
What Comes Next For Dentsply Sirona
Dentsply Sirona’s quarter shows a company genuinely improving its margins and cash generation while its revenue keeps contracting. Whether the reiterated 2026 guidance holds will likely hinge on segments like Orthodontic and Implant Solutions and the Americas region stabilizing rather than continuing their double-digit declines. The widening constant currency sales drop and the shrinking cash balance give skeptics reason to stay cautious even as the income statement improves.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Follow Insider Monkey on Google News.
